India Medtronic, a wholly owned subsidiary of Ireland-headquartered Medtronic plc, has announced the launch of the Symplicity Spyral renal denervation system (RDN) for treating high blood pressure.

RDN is a minimally invasive therapy that targets nerves near the kidneys that can become overactive and cause high blood pressure. Medtronic recently announced the US Food and Drug Administration’s (FDA) approval of the system which is a culmination of ten years of clinical research and development, and the system has approval of the Indian regulatory authorities too.

In India, nearly 1 in 4 adults have hypertension. Hypertension is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure.  

The Symplicity Spyral blood pressure procedure has demonstrated clinical efficacy in reducing high blood pressure which can lower serious health risk. It is a minimally invasive procedure that targets nerves near the kidneys that can become overactive and cause elevated blood pressure. After sedation, the doctor makes a small incision and inserts a very thin tube (catheter) into the artery leading to the kidney. The doctor then uses the catheter to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind.

Michael Blackwell, Vice President and Managing Director, Medtronic India said, "With the Symplicity blood pressure procedure, we aim to empower healthcare professionals and offer a comprehensive approach to managing uncontrolled hypertension that supports our patient-centered approach to care."